Chambers Associate: What are the areas of activity in the life sciences sector? Litigation in the pharmaceutical and biotechnology industries can be particularly complex and requires advice that knows both scientific disciplines and law. Goodwin has made meeting the needs of the pharmaceutical and biotechnology industries a strategic priority for more than two decades, and we have one of the largest and most active life sciences practices in the United States. Our intellectual property litigation team is among the most experienced in the country and successfully represents branded and generic companies in Hatch-Waxman litigation. Our client portfolio includes some of the world`s largest innovators and generics companies, and we have represented our clients in patent cases involving some of the world`s largest blockbuster medicines. The fundamental questions of whether and to what extent genetic engineering should be used must be decided democratically, but the detailed drafting of laws requires legal expertise. That`s where legal research comes in. It covers a wide range of current topics, from genetic engineering to stem cell research and new drugs. Basel offers an ideal setting for this. The Centre for Life Sciences Law at the Faculty of Law of the University of Basel aims to make an important contribution to research and teaching in this field.
Clark Zhang, Partner: There are a variety of areas of activity, ranging from corporations to intellectual property (e.g., patenting, patent litigation, licensing, trademarks). In patenting processes, for example, life sciences include small molecules, biologics, and even computer applications of the life sciences. The intersection of business, science and law presents life sciences companies with unique challenges. Morgan Lewis understands the implications of this critical relationship, and our lawyers work effectively and strategically to resolve the commercial, transactional, regulatory, intellectual property rights, litigation and related issues our clients face throughout the product lifecycle. We are leaders in meeting the needs of companies ranging from pure start-ups to commercial biopharmaceuticals and everything in between, as well as investors, banks and every other company in the life sciences ecosystem that support these companies. Our team excels in complex transactions, high-stakes litigation and advisory services to support the most innovative companies in the life sciences industry. Our unique combination of experience serving both innovators and investors in a changing and technology-driven economy continues to set us apart. Our customers come from the United States and around the world. As a life sciences firm, our lawyers have hands-on experience in the life sciences industry, hold graduate degrees in science and technology, regularly write articles in industry-related publications, and frequently present to industry-specific groups.
Life science law is an umbrella term that encompasses a wide range of scientific discoveries, political judgments and legal issues affecting the development, production, distribution and use of pharmaceuticals, biotechnology products and medical devices. Other relevant areas include diet, dietary supplements, plant technology, animal husbandry and other aspects of human and animal nutrition, health or productivity. In each case, important underlying considerations are taken into account, including safety, efficiency, societal necessity, cost, environmental impact and technological development. Our lawyers understand the essential link between law, business and academia. We regularly assist life sciences companies – and the companies that invest in them – with inbound and outbound activities in China, Japan, Korea, Australia and Southeast Asia, including Singapore, Indonesia, Malaysia, the Philippines, Thailand, Vietnam and Myanmar. Succeeding in the life sciences industry is a matter of strategy and execution as well as research and development. And with the rapid pace of technology revolutionizing industries globally, Goodwin`s extensive experience not only in life sciences, but also working with our technology, healthcare, real estate and private equity lawyers, makes our team uniquely qualified to handle whatever the future holds. Our life sciences lawyers work with their clients to harness the promise and potential of innovation to make a profound and lasting impact.
Price pressures, the redemption landscape, margin erosion, low valuations and the favorable tax policy climate are just some of the factors positioning the life sciences sector for accelerated M&A activity. The climate will be competitive for both buyers and sellers, and expert legal advice is essential for companies to take advantage of attractive strategic opportunities. Do you think of mergers and acquisitions, even as a wink in your strategic plan? Goodwin can help. For more than 30 years, Wiggin and Dana`s lawyers have served a diverse group of life sciences clients, including the world`s largest healthcare companies, mid-market public and private biotechnology companies, university spin-offs, individual scientists and entrepreneurs – in their most important fields, Our global life sciences capabilities have been developed specifically for the pharmaceutical, biotechnology, medical device and related industries, as well as related industries. companies that invest in it, such as venture capital and private equity funds. Our multinational lawyers in Singapore, Beijing, Hong Kong, Shanghai and Tokyo advise clients in all life sciences sectors. Across the region, our team represents capital markets clients; mergers and acquisitions; licensing and collaborations; Private equity; financing and restructuring; intellectual property; economic, governmental and internal investigations; work and employment; and international tax planning. In addition to global pharmaceutical, biotech and medtech companies, we also serve other companies in the sector, including investment banks. private equity, venture capital and royalty monetisation firms; precision medicine and digital health companies; contract research and contract manufacturing organizations; institutional lenders; committees of independent directors; and management groups.